- Home
- Equipment
- north america
- coronary artery bypass graft
Show results for
Refine by
Coronary Artery Bypass Graft Equipment Supplied In North America
7 equipment items found
Manufactured by:XyloCor Therapeutics based inWayne, PENNSYLVANIA (USA)
Coronary Artery Bypass Graft Surgery or CABG is a procedure used to treat coronary artery disease – the narrowing or blockage of the blood vessels that supply oxygen and nutrients to the heart muscle. During CABG, a healthy artery or vein from the body is connected, or ...
Manufactured by:XyloCor Therapeutics based inWayne, PENNSYLVANIA (USA)
XC001 is an investigational gene therapy for the treatment of patients with refractory angina with no treatment options. Patients who have exhausted pharmacologic options and are not eligible for PCI or coronary artery bypass grafts become sedentary because of their symptoms and this can exacerbate comorbidities causing rapid ...
Manufactured by:AtriCure, Inc. based inMason, OHIO (USA)
The Isolator Synergy ablation clamp is the FIRST and ONLY surgical ablation device offered with FDA approval for the treatment of Atrial Fibrillation (Afib) and the only device either Catheter or Surgical to be approved for the treatment of persistent and long-standing persistent ...
Manufactured by:CeloNova BioSciences, Inc. based inCarlsbad, CALIFORNIA (USA)
COBRA PzF NCS is the world’s first non-drug eluting, nanocoated stent that allows physicians to safely and effectively treat their patients who may benefit from a short, minimum 1-month DAPT ...
Manufactured by:MedChemExpress LLC (MCE) based inMonmouth Junction, NEW JERSEY (USA)
Aprotinin is a bovine pancreatic trypsin inhibitor (BPTI) inhibitor which inhibits trypsin and chymotrypsin with Kis of 0.06 pM and 9 nM, ...
Manufactured by:Palisade Bio based inCarlsbad, CALIFORNIA (USA)
Our lead asset LB1148 is a novel oral liquid formulation of the well-characterized digestive enzyme inhibitor, tranexamic acid (“TXA”), with potential to both reduce abdominal adhesions and help restore bowel function following surgery. The therapy is being developed for administration prior to major surgeries that are at risk of disrupting the intestinal epithelial ...
Manufactured by:Vascudyne, Inc. based inStillwater, MINNESOTA (USA)
Synthetic vascular grafts currently used in clinic have poor long term outcomes and low patency rates. Hyperplasia, calcification, foreign body immune response, infection, and atheroma formation are commonly encountered limiting the use of synthetic grafts, with none available for small diameter applications like coronary ...